PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in Parkinson's Patients
6/12/2012 10:12:59 AM
TARRYTOWN, N.Y.--(BUSINESS WIRE)--PsychoGenics Inc. today reported positive results from a clinical study of eltoprazine in levodopa induced dyskinesia (LID) in Parkinson's disease (PD) patients. Eltoprazine met the primary objective of the study by exhibiting a statistically significant reduction in LID at the 5 mg dose (p = 0.0007) and the 7.5 mg dose (p = 0.0467), without adversely affecting levodopa efficacy. Eltoprazine was also well tolerated in this study and there were no serious adverse events.